Chronic migraine patients who used GLP-1 receptor agonists to treat conditions like obesity or diabetes had fewer emergency department (ED) visits than those on topiramate (Topamax), a real-world data analysis showed.
Compared with topiramate users, GLP-1 drug initiators were 10% less likely to visit the ED over the following year (RR 0.90, 95% CI 0.86-0.94), reported Hsiangkuo Yuan, MD, PhD, of Jefferson Headache Center at Thomas Jefferson University in Philadelphia, in an abstract released ahead of the American Academy of Neurology annual meeting.
Chronic migraineurs who started GLP-1 drugs also were 14% less likely to be hospitalized (RR 0.86, 95% CI 0.81-0.91), and were 13% less likely to have a nerve block (RR 0.87, 95% CI 0.78-0.97) or receive a triptan prescription (RR 0.87, 95% CI 0.84-0.91), compared with those who started taking topiramate.
The GLP-1 receptor agonist group was less likely to start tricyclic antidepressants (RR 0.65), valproate (RR 0.52), oral or nasal calcitonin gene-related peptide (CGRP) receptor antagonists (RR 0.77), CGRP monoclonal antibodies (RR 0.58), or serotonin-norepinephrine reuptake inhibitors (RR 0.80) than the topiramate group. There was no significant difference in beta-blocker initiation between groups.
“This study suggests a possible signal that people with chronic migraine who start a GLP‑1 receptor agonist may end up needing fewer acute‑care visits and fewer additional triptans or preventive migraine medications over time compared with those starting topiramate, a commonly used migraine preventive,” Yuan observed.
“Because this analysis cannot determine the cause of these differences, we don’t know whether GLP‑1 receptor agonists help migraine directly, whether any improvements relate to broader effects such as better metabolic health, weight loss, or reduced inflammation, or whether the findings simply reflect the limitations of topiramate in real‑world use,” Yuan told MedPage Today.
“Still, seeing a pattern of lower overall healthcare use may give patients hope that these medications could offer benefits beyond metabolic effects and highlights the need for future prospective studies to determine whether GLP‑1 receptor agonists truly help with migraine prevention,” he added.
GLP-1 receptor agonists exert anti-inflammatory and neurovascular effects that may influence migraine pathophysiology, but no large-scale trials have assessed whether they prevent migraine. A prospective pilot study in Italy last year reported that adjunctive use of the GLP-1 agent liraglutide (Saxenda) reduced mean monthly headache days in people with refractory high-frequency or chronic migraine and obesity from 19.8 to 10.7 days.
This benefit was independent of weight loss, noted researcher Roberto De Simone, MD, of the University of Naples Federico II in Italy. “This suggests that the mechanism of action is not solely linked to the well‑known association between excess weight and migraine worsening, but may instead involve additional biological pathways,” he told MedPage Today.
“The GLP‑1 receptor is expressed in the choroid plexus, and experimental studies have shown that its activation can reduce cerebrospinal fluid production more effectively than either acetazolamide or topiramate,” De Simone continued. “In animal models of chronic migraine, GLP‑1 receptor agonists have been reported to suppress CGRP expression and dampen central sensitization within the trigeminal nucleus caudalis,” he pointed out.
The pilot study data “support the hypothesis that altered regulation of intracranial pressure may represent a shared pathogenic step underlying both idiopathic intracranial hypertension and migraine,” De Simone noted. “This could account for the remarkable overlap between the two disorders, not only in their clinical presentation but also in their major risk factors like female sex, obesity, and sleep disorders,” plus their elevated circulating CGRP levels and their shared high prevalence of venous sinus stenosis, he added.
Yuan and colleagues used TriNetX data to evaluate information about 10,997 adults with chronic migraine who started using a GLP-1 agent — liraglutide, semaglutide (Ozempic, Wegovy, Rybelsus), dulaglutide (Trulicity), exenatide (Byetta), lixisenatide (Adlyxin), or albiglutide (Tanzeum) — within 12 months of diagnosis, and 10,997 who initiated topiramate. Chronic migraine was defined as headache on at least 15 days a month for 3 months or longer, with migraine symptoms on at least 8 of those days.
The GLP-1 receptor agonist and topiramate groups were propensity-score matched on demographics, BMI, comorbidities, and prior preventive migraine drug use. The study population had an average age of 48 and 87.8% were women.
The findings suggest a potential role of GLP-1 drug in migraine management and warrant prospective evaluation, Yuan and co-authors said. While the groups were balanced at baseline, variables that may have changed over the year — weight loss, migraine severity, medication use patterns, or lifestyle changes — were not accounted for and may have influenced outcomes.
